Markets:

Overview

News

Currencies

International

Treasuries

HEALTHCARE (NY:XLV)

156.25 +0.92 (+0.59%)

Official Closing Price Updated: 6:30 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about HEALTHCARE

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

42 43 Next >

Is It Time To Shift Focus To Beaten-Down Healthcare Stocks As Volatility Soars? ↗

March 04, 2025

Healthcare performed terribly in 2023 and 2024, falling while the market was soaring. Year-to-date, the sector has outperformed. Is it time to focus on the stocks and ETFs of this low-Beta sector as...

Via Talk Markets

Topics ETFs Stocks / Equities

Biotech Rally Coming In Weeks Ahead? ↗

March 04, 2025

Large cap biopharma and MedTech stocks are leading the healthcare sector higher.

Via Talk Markets

Topics ETFs Stocks / Equities

Leading And Lagging Sectors For March 4, 2025 ↗

March 04, 2025

Via Benzinga

Making Bets On The Money ↗

March 03, 2025

The top-performing sector last week was financials, they closed up over 2.8% on the week at their highest weekly and monthly level in history.

Via Talk Markets

Topics Stocks / Equities

Leading And Lagging Sectors For March 3, 2025 ↗

March 03, 2025

Via Benzinga

US Sector Leadership Shifts, Favoring Healthcare Stocks ↗

February 27, 2025

Via Talk Markets

Topics ETFs

Leading And Lagging Sectors For February 28, 2025 ↗

February 28, 2025

Via Benzinga

Moderna Stock Heads For Weekly Loss As Retail Caution Prevails: Wealth Advisor Tells Why She's Staying On The Sidelines ↗

February 28, 2025

The stock fell over 7% on Thursday after reports that federal health officials under the Trump administration are re-evaluating Moderna's $590 million contract for bird flu vaccine development.

Via Stocktwits

Topics Government

Leading And Lagging Sectors For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Leading And Lagging Sectors For February 26, 2025 ↗

February 26, 2025

Via Benzinga

Leading And Lagging Sectors For February 25, 2025 ↗

February 25, 2025

Via Benzinga

Biotech Stocks Stay Strong Through A Period Of Uncertainty In The Market ↗

February 24, 2025

Many analysts are feeling better about the prospects for healthcare stocks in 2025.

Via Talk Markets

Topics ETFs Stocks / Equities

Staples Surge On A Dime ↗

February 24, 2025

We’re starting to see money flows into more defensive sectors of the market. This is rather concerning in the near-term.

Via Talk Markets

Topics Stocks / Equities

Leading And Lagging Sectors For February 24, 2025 ↗

February 24, 2025

Via Benzinga

NIH Funding Cuts To Spook Healthcare Stocks? RFK Jr's Confirmation At HHS Sparks Concerns Over Research Dollars, 'Causing Uncertainty,' Says Analyst ↗

February 24, 2025

Robert F. Kennedy Jr.'s appointment as Secretary of Health and Human Services has sparked concerns over funding for the NIH.

Via Benzinga

Leading And Lagging Sectors For February 21, 2025 ↗

February 21, 2025

Via Benzinga

Leading And Lagging Sectors For February 20, 2025 ↗

February 20, 2025

Via Benzinga

Medtronic Logs Worst Day In Nearly 5 Years On Q3 Revenue Miss, But Retail Goes Bargain Hunting ↗

February 18, 2025

The company said its medical-surgical segment struggled with ongoing stapling market pressures and temporary shifts in U.S. distributor buying patterns.

Via Stocktwits

Biotech Stocks Had A Good Week Despite Crosscurrents ↗

February 18, 2025

It’s too early to account for the rally but in general one can say that there is a lot of speculation from both the retail side and hedge funds.

Via Talk Markets

Topics ETFs Stocks / Equities

Leading And Lagging Sectors For February 18, 2025 ↗

February 18, 2025

Via Benzinga

Health Insurance ETFs in Focus as RFK Jr Takes Over HHS ↗

February 17, 2025

Robert F. Kennedy Jr. has taken office as HHS secretary, which could impact the healthcare sector, including ETFs with exposure to insurers like UnitedHealth and Elevance Health.

Via Benzinga

Topics ETFs

Leading And Lagging Sectors For February 17, 2025 ↗

February 17, 2025

Via Benzinga

China, Gold, Momentum Lead, But Surprisingly Savvy Investors Turn Bearish ↗

February 16, 2025

Momentum stocks are leading the market higher, but this is much different leadership than what elevated the market in 2024.

Via Talk Markets

Topics ETFs Stocks / Equities

Moderna’s Q4 Losses Worse Than Feared, But Revenue Beat And Cost Cuts Boost Stock — Retail Sentiment Follows ↗

February 14, 2025

CEO Stéphane Bancel said the company remains focused on driving sales and achieving up to 10 product approvals by 2027, as well as removing nearly $1 billion in costs by the end of this year.

Via Stocktwits

CVS Showered With Upgrades, PT Hikes After Q4 Beat Powers Stock To Best Day In Over 25 Years: Retail Cheer Grows ↗

February 13, 2025

Analysts largely believe that the company’s Aetna insurance business is set to rebound and its margins will recover soon.

Via Stocktwits

Biogen Stock Slides To Fresh 12-Year Lows As Profit Outlook Misses, But Retail Snaps Up The Dip ↗

February 12, 2025

The company's breakthrough Alzheimer's drug, Leqembi, generated $87 million in Q4 sales, well ahead of the $67 million analysts expected.

Via Stocktwits

Gilead Wins Price-Target Boosts After Solid Q4, Retail Brushes Off Medicare Reform Hit To HIV Drugs ↗

February 12, 2025

Investors seem encouraged by the company's strong performance in its core business areas and the promise of further growth driven by its expanding pipeline.

Via Stocktwits

Leading And Lagging Sectors For February 12, 2025 ↗

February 12, 2025

Via Benzinga

Beginnings And Blends: S&P 500 Sector Performance In The New Year ↗

February 11, 2025

No matter how vast the index landscape becomes, sectors remain central to the conversation.

Via Talk Markets

Topics Stocks Stocks / Equities

Vertex Pharma Stock Flooded With Price-Target Hikes After Upbeat Q4 Revenue, 2025 Outlook: Retail Stays Bullish ↗

February 11, 2025

The company is betting on strong sales of its cystic fibrosis drugs and early traction from its newly approved non-opioid painkiller.

Via Stocktwits

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

HEALTHCARE (NY:XLV)

All News about HEALTHCARE

Starting at $3.75/week.

Subscribe Today